Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study-Reference-Cited by-同舟云学术

Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study

Published:2014-02-07 Issue:4 Volume:165 Page:489-496
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Wieringa Andre¹²,Boslooper Karin³,Hoogendoorn Mels⁴,Joosten Peter⁴,Beerden Tim¹,Storm Huib⁵,Kibbelaar Robby E.⁶,Veldhuis Gerrit J.⁷,van Kamp Harmen⁸,van Rees Bastiaan⁹,Kluin-Nelemans Hanneke C.³,Veeger Nic J. G. M.¹⁰,van Roon Eric N.¹¹¹

Affiliation:

1. Department of Pharmacotherapy & Pharmaceutical Care; University Centre for Pharmacy; University of Groningen; Groningen The Netherlands

2. Department of Clinical Pharmacy; Isala Klinieken; Zwolle The Netherlands

3. Department of Haematology; University Medical Centre Groningen; University of Groningen; Groningen The Netherlands

4. Department of Haematology; Medical Centre Leeuwarden; Leeuwarden The Netherlands

5. Department of Clinical Chemistry; Medical Centre Leeuwarden KCL; Leeuwarden The Netherlands

6. Department of Pathology; Pathology Friesland; Leeuwarden The Netherlands

7. Department of Haematology; Antonius Hospital; Sneek The Netherlands

8. Department of Haematology; Nij Smellinghe Hospital; Drachten The Netherlands

9. Department of Haematology; Tjongerschans Hospital; Heerenveen The Netherlands

10. Department of Epidemiology; MCL Academy; Leeuwarden The Netherlands

11. Department of Clinical Pharmacy & Pharmacology; Medical Centre Leeuwarden; Leeuwarden The Netherlands

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12765/fullpdf

Reference28 articles.

1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;European Journal of Cancer,2011

2. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer;Birim;European Journal of Cardio-Thoracic Surgery,2005

3. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome;Boslooper;Leukemia & Lymphoma,2013

4. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation;Charlson;Journal of Chronic Diseases,1987

5. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting;Clinical Lymphoma Myeloma and Leukemia;2024-05

2. Higher Mortality in Patients With Diffuse Large B-cell Lymphoma Pre-Existing Arterial Hypertension—Real World Data of the Polish Lymphoma Research Group;Heart, Lung and Circulation;2024-05

3. Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study;The Korean Journal of Internal Medicine;2024-05-01

4. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma;Future Oncology;2023-12-05

5. Frailty assessment to individualize treatment in older patients with lymphoma;European Geriatric Medicine;2023-10-12